P‐glycoprotein (MDR1/ABCB1)

Cascorbi, Ingolf

doi:10.1002/9781118353240.ch12

Cited by 2 publications

(1 citation statement)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The basal expression of P‐gp has been found in several normal tissues, such as liver, intestine, kidney, testes, placenta, and blood brain barrier to provide protection against xenobiotics and toxic substances. 25 The P‐gp transporters are the most commonly summoned transporter proteins and they play a critical role in the development of drug resistance in cancer cells. Several biochemical changes are associated with multidrug resistant cancer cells, where overexpression of P‐gp is the most common phenomenon in many types of cancers.…”

Section: Mechanisms Of Drug Resistancementioning

confidence: 99%

Molecular and cellular paradigms of multidrug resistance in cancer

et al. 2020

View full text Add to dashboard Cite

Background: The acquisition of resistance to chemotherapy is a major hurdle in the successful application of cancer therapy. Several anticancer approaches, including chemotherapies, radiotherapy, surgery and targeted therapies are being employed for the treatment of cancer. However, cancer cells reprogram themselves in multiple ways to evade the effect of these therapies, and over a period of time, the drug becomes inactive due to the development of multi-drug resistance (MDR). MDR is a complex phenomenon where malignant cells become insensitive to anticancer drugs and attain the ability to survive even after several exposures of anticancer drugs. In this review, we have discussed the molecular and cellular paradigms of multidrug resistance in cancer.Recent Findings: An Extensive research in cancer biology revealed that drug resistance in cancer is the result of perpetuated intracellular and extracellular mechanisms such as drug efflux, drug inactivation, drug target alteration, oncogenic mutations, altered DNA damage repair mechanism, inhibition of programmed cell death signaling, metabolic reprogramming, epithelial mesenchymal transition (EMT), inherent cell heterogeneity, epigenetic changes, redox imbalance, or any combination of these mechanisms. An inevitable cross-link between inflammation and drug resistance has been discussed. This review provided insight molecular mechanism to understand the vulnerabilities of cancer cells to develop drug resistance. Conclusion:MDR is an outcome of interplays between multiple intricate pathways responsible for the inactivation of drug and development of resistance. MDR is a major obstacle in regimens of successful application of anti-cancer therapy. An improved understanding of the molecular mechanism of multi drug resistance and cellular reprogramming can provide a promising opportunity to combat drug resistance in cancer and intensify anti-cancer therapy for the upcoming future.

show abstract

Section: Mechanisms Of Drug Resistancementioning

confidence: 99%

Molecular and cellular paradigms of multidrug resistance in cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

Advances of Proteomics Technologies for Multidrug-Resistant Mechanisms

Zhang

Yuan

et al. 2019

Future Med. Chem.

View full text Add to dashboard Cite

Multidrug resistance (MDR) is a vital issue in cancer treatment. Drug resistance can be developed through a variety of mechanisms, including increased drug efflux, activation of detoxifying systems and DNA repair mechanisms, and escape of drug-induced apoptosis. Identifying the exact mechanism related in a particular case is a difficult task. Proteomics is the large-scale study of proteins, particularly their expression, structures and functions. In recent years, comparative proteomic methods have been performed to analyze MDR mechanisms in drug-selected model cancer cell lines. In this paper, we review the recent developments and progresses by comparative proteomic approaches to identify potential MDR mechanisms in drug-selected model cancer cell lines, which may help understand and design chemical sensitizers.

show abstract

P‐glycoprotein (MDR1/ABCB1)

Cited by 2 publications

References 125 publications

Molecular and cellular paradigms of multidrug resistance in cancer

Molecular and cellular paradigms of multidrug resistance in cancer

Advances of Proteomics Technologies for Multidrug-Resistant Mechanisms

Contact Info

Product

Resources

About